Swiss pharmaceutical company Roche announced on Thursday a partnership with Ibex Medical Analytics and Amazon Web Services to accelerate the adoption of AI-enabled digital pathology solutions that would help improve cancer diagnoses.
The collaboration would enable pathology laboratories to access Ibex's powered by artificial intelligence (AI) decision support tools to support clinicians in breast and prostate cancer diagnosis through the navify digital pathology software platform.
Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services, enabling a scalable and sustainable ecosystem for pathology laboratories.
Ibex's AI algorithms would help clinicians in the diagnosis of breast and prostate biopsies and provide efficient, accurate and timely cancer diagnosis, support case prioritization, determine the cancer grading and subtype, and identify important non-cancerous features, the company said.
The Ibex algorithms used at laboratories and hospitals worldwide, are currently for research use only, not for use in diagnostic procedures, in the United States.
